County of San Luis Obispo Public Health Department

Division: Emergency Medical Services Agency

<u>DOPAMINE (Intropin®)</u> (Base Hospital Order Only)

Classification: Sympathomimetic agent (catecholamine)

Actions: Moderate Dose: (5-10 mcg/kg/min) (β receptors)

- 1. Increases inotropy and may increase chronotropy
- 2. Increases BP by stimulating β1 receptors increasing cardiac output with small increase in peripheral vascular resistance.

Dopamine (Intropin®)

Effective Date: 04/15/2017

High Dose: (Over 10-20 mcg/kg/min) (primarily α receptors, some β)

- 1. Causes vasoconstriction
- 2. Increases inotropy and chronotropy
- 3. Increases BP by stimulating α and β 1 receptors

Indications:

- 1. Symptomatic bradycardia persisting after prior therapies
- Cardiogenic shock with signs/symptoms of CHF or not responding to fluid challenge
- 3. Hypotension

Contraindications:

- 1. Hypovolemia
- 2. Tachydysrhythmias

Adverse Effects: Cardiovascular Respiratory

Tachycardia dyspnea

Hypertension increase O2 demand

Ventricular irritability

Chest pain

Gastrointestinal Nausea/vomiting

Administration: ADULT DOSE

400 mg in 250 ml NS (1600 mcg/ml) IV drip, by base physician order: 5-20

mcg/kg/min, titrated to blood pressure.

PEDIATRIC DOSE

400 mg in 250 ml NS (1600 mcg/ml) IV drip, by base physician order: 5-20

mcg/kg/min, titrated to blood pressure.

Onset: 5 minutes

Duration: 5-10 minutes

DOPAMINE (Intropin®) (Base Physician Order Only) CONTINUED

Notes:

- Consider expediting transport in cases requiring Dopamine administration.
- Dopamine may be inactivated by alkaline solutions such as Sodium Bicarbonate.
- Start in the largest possible vein and ensure patency prior to administration, as Dopamine is likely to cause tissue necrosis upon entering the interstitial space.
- Establish a second IV line for other medications, as the Dopamine infusion should not be interrupted.
- In the upper end of the moderate dosage range, α receptors are stimulated and peripheral vasoconstriction occurs.
- In the high dose range, α receptors override the dopaminergic receptors, resulting in decreased renal and mesenteric perfusion.

| | | Dose | | | |
|------------|-----|-----------------------|-----------|-----------|-----------|
| Weight in: | | 5 mcg/kg | 10 mcg/kg | 15 mcg/kg | 20 mcg/kg |
| lbs | kg | Microdrips per Minute | | | |
| 100 | 45 | 9 | 17 | 26 | 34 |
| 110 | 50 | 9 | 19 | 28 | 38 |
| 120 | 55 | 10 | 20 | 31 | 41 |
| 130 | 59 | 11 | 22 | 33 | 44 |
| 140 | 64 | 12 | 24 | 36 | 48 |
| 150 | 68 | 13 | 26 | 38 | 51 |
| 160 | 73 | 14 | 27 | 41 | 55 |
| 170 | 77 | 14 | 29 | 43 | 58 |
| 180 | 82 | 15 | 31 | 46 | 61 |
| 190 | 86 | 16 | 32 | 49 | 65 |
| 200 | 91 | 17 | 34 | 51 | 68 |
| 210 | 95 | 18 | 36 | 54 | 72 |
| 220 | 100 | 19 | 38 | 56 | 75 |
| 230 | 105 | 20 | 39 | 59 | 78 |
| 240 | 109 | 20 | 41 | 61 | 82 |
| 250 | 114 | 21 | 43 | 64 | 85 |
| 260 | 118 | 22 | 44 | 66 | 89 |
| 270 | 123 | 23 | 46 | 69 | 92 |
| 280 | 127 | 24 | 48 | 72 | 95 |
| 290 | 132 | 25 | 49 | 74 | 99 |
| 300 | 136 | 26 | 51 | 77 | 102 |
| 310 | 141 | 26 | 53 | 79 | 106 |
| 320 | 145 | 27 | 55 | 82 | 109 |
| 330 | 150 | 28 | 56 | 84 | 113 |
| 340 | 155 | 29 | 58 | 87 | 116 |